Dataset Information

Uveal melanoma cell lines are representative for their tumour, except cell lines Mel285 and Mel290: the odd two out

ABSTRACT: Purpose: In uveal melanoma (UM) research, several cell lines are used in preclinical studies. Because Mel285 and Mel290 do not harbour typical GNAQ or GNA11 hotspot mutations, we aimed at better classifying them and understanding if we could find genetic causes to explain their protein and mRNA expression profiles. Methods: We studied protein and mRNA expression in 14 UM cell lines and determined the presence of Single Nucleotide Variants and small Insertions and Deletions with next generation sequencing and copy number alterations (CNAs) with a single nucleotide polymorphism array. The lists of differentially expressed proteins and genes were merged, and shared lists were created, keeping only the terms with concordant mRNA and protein expression. Enrichment analysis and Gene Set Enrichment Analysis were performed on the shared lists. Results: Mel285 and Mel290 are distinct from the GNA-mutated cell lines and have downregulation of melanosome-related markers. Mel285 and Mel290 lack typical UM mutations but harbour putatively-deleterious variants in four genes each (Mel285: CTNNB1, PPP1R10, LIMCH1, APC; Mel290: ARID1A, PPP1R10, SPG11, RNF43). The upregulated terms in Mel285 and Mel290 did not point to a convincing alternative origin. Mel285 has several CNAs, among which loss of 1p, 3p, partial 3q, 6 and partial 8p, while Mel290 shows 1p loss and chromosome 6 loss. Conclusion: While Mel285 and Mel290 have some CNAs that resemble those in UM, multi-omics analyses show that they belong to a separate group compared to the other analysed UM cell lines. Therefore, they may not be representative models to test potential therapeutic targets for UM.

INSTRUMENT(S): Orbitrap Exploris 480

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Cell Culture

SUBMITTER: Rayman Tjokrodirijo

LAB HEAD: Peter A. van Veelen

PROVIDER: PXD051055 | Pride | 2024-07-16

REPOSITORIES: Pride

ACCESS DATA

Dataset's files

Source:

Items per page:

1 - 5 of 41

Similar Datasets

Project description:Viswanathan SR, Nogueira MF, Buss CG, Krill-Burger JM, Wawer MJ, Malolepsza E, Choi PS, Berger A, Shih J, Tanenbaum B, Strathdee CA, Tamayo P, Pedamallu CS, Vazquez F, Lage K, Carr SA, Schenone M, Bhatia SN, Cherniack AD, Tsherniak A, Hahn WC, Meyerson M. Nature Genetics 2018. Chromosome arm-level deletion events are highly prevalent across cancer types. The targeting of functionally redundant paralog genes required for cell viability has been proposed as a potential therapeutic strategy to selectively kill cancer cells with chromosome arm deletions. Here, we identify MAGOHB as a novel therapeutic target for chromosome 1p deleted cancer through an analysis of paralog dependencies emerging from genome-wide shRNA screening of cancer cell lines. MAGOHB and its functionally redundant paralog, MAGOH, are core members of the exon-junction complex (EJC), a multi-protein complex that is deposited at exon-exon junctions after mRNA splicing and that has important roles in regulating pre-mRNA splicing, mRNA transport, and nonsense-mediated decay (NMD) MAGOHB is the top differential dependency in cells with hemizygous loss of MAGOH, a pervasive passenger genetic event across multiple tumor types that frequently occurs in the context of chromosome 1p loss. Inhibition of MAGOHB in cells with deletion of MAGOH compromises viability by globally perturbing alternative splicing and RNA surveillance, resulting in an accumulation of premature-termination codon-containing transcripts. We further identify IPO13, a bidirectional karyopherin that mediates nuclear import of the MAGOH/B-Y14 heterodimer as a potentially druggable target whose dependency is highly correlated to both MAGOH and MAGOHB dependency, suggesting a rationale for inhibiting MAGOH/MAGOHB function by interfering with EJC recycling. Finally, we validate MAGOHB as a target in vivo through delivery of a tumor-penetrating peptide-siRNA nanocomplex. Our results define MAGOH and MAGOHB as reciprocal paralog dependencies across cancer types and identify the MAGOHB-IPO13 axis as an potential therapeutic target in MAGOH-deleted cancers and in cancers with chromosome 1p deletion.

Project description:Purpose: The most clearly established genetic hallmark in oligodendroglial tumors (OTs) is the combined loss of 1p/19q, a molecular alteration characteristic of tumors responding to therapy. Markers of tumoral progression have not yet been studied. Experimental Design: Novel markers of tumoral progression in OTs were sought through gene expression profiling analysis. Results: Unsupervised hierarchical cluster analysis classified OTs into two main groups associated with tumoral grade, independent of histological subtype and 1p/19q status. Differential gene expression analysis between low- and high-grade OTs revealed that only cell cycle-related genes were significantly upregulated in high-grade OTs. Among the deregulated genes, NDRG2 downregulation was detected in high-grade OTs with combined loss of 1p/19q. Expression analysis revealed low transcript levels of NDRG2 relative to non-tumoral brain tissue in 45% (9/20) of high-grade OTs. Furthermore, the low transcript levels of NDRG2 were significantly associated with a worse clinical outcome in patients. Transcript levels of NDRG2 were associated with promoter hypermethylation, which was detected in 38.4% (10/26) of high-grade OTs. The treatment of glioma cell lines T98 and LN18 with demethylating agents increased the mRNA expression levels of NDRG2 relative to the control cell line. Additionally, cell proliferation was significantly reduced and cell cycle was arrested in G1 phase after treatment with demethylating agents. Conclusions: Taken together, our results suggest that NDRG2 is a candidate tumor suppressor gene in OTs whose inactivation could be involved in tumoral progression and worse patient survival. The microarray study involved 28 glioma samples including oligodendrogliomas and oligoastrocytomas WHO grade II and III. Six non-tumoral brain tissues were used as controls, two of which were purchased from Stratagene (La Jolla, CA) and Clontech (Mountain View, CA). RNAs from several cell lines (Universal Human RNA, Stratagene, La Jolla, CA) was used as a standard reference in all hybridizations

			Action	DRS
	E20222002422a.raw	Raw
	E20222002423a.raw	Raw
	E20222002424a.raw	Raw
	E20222002425a.raw	Raw
	E20222002426a.raw	Raw

Dataset Information

Uveal melanoma cell lines are representative for their tumour, except cell lines Mel285 and Mel290: the odd two out

Dataset's files

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets